Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + ginsenoside
- Development stage
- Preclinical
- Lead developer
- Hangzhou Jinshennuo Biopharmaceutical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Epirubicin + ginsenoside is a liposomal formulation of the anthracycline chemotherapy agent epirubicin, developed by Xiamen Ginposome Pharmaceutical using its proprietary Ginposome drug delivery system (DDS). This technology utilizes ginsenosides, specifically ginsenoside Rg3, as a functional membrane material to encapsulate the drug. Epirubicin works by intercalating into DNA and inhibiting topoisomerase II, which triggers DNA cleavage and inhibits both DNA and RNA synthesis. The ginsenoside-based liposomal delivery is designed to enhance the stability and tumor-targeting capabilities of epirubicin while potentially reducing systemic toxicity. While Xiamen Ginposome has other ginsenoside-liposomal products in late-stage clinical development (such as formulations of paclitaxel and docetaxel), the epirubicin formulation is currently identified in the company's patent and early pipeline listings.
- Other names
- epirubicin ginsenoside liposomeepirubicin liposomal formulation (ginsenoside membrane)
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on epirubicin + ginsenoside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + ginsenoside.